BLRX Bioline Rx Ltd

Price (delayed)

$2.82

Market cap

$14.72M

P/E Ratio

N/A

Dividend/share

N/A

EPS

$0

Enterprise value

$6.44M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 15

biolinerx is a clinical-stage, publicly-traded (nasdaq/ tase: blrx) biopharmaceutical development company based in modi'​in, israel. this website or social media page (the “site”) of biolinerx ltd. (the “company”) may contain ...

Highlights
The debt has declined by 34% year-on-year and by 11% since the previous quarter
Bioline Rx's gross margin has increased by 22% YoY
The revenue has plunged by 94% YoY but it has grown by 19% from the previous quarter
The company's gross profit has shrunk by 92% YoY but it rose by 17% QoQ
BLRX's net income has shrunk by 162% YoY
Bioline Rx's quick ratio has decreased by 30% YoY and by 20% QoQ

Key stats

What are the main financial stats of BLRX

BLRX stock price

How has the Bioline Rx stock price performed over time
Intraday
-1.4%
1 week
-2.76%
1 month
-16.32%
1 year
-37.47%
YTD
1.81%
QTD
-9.62%

Financial performance

How have Bioline Rx's revenue and profit performed over time
Revenue
$1.4M
Gross profit
$1.11M
Operating income
-$10.9M
Net income
-$8.89M
Gross margin
79.2%
Net margin
-634.1%
BLRX's net income has shrunk by 162% YoY
The revenue has plunged by 94% YoY but it has grown by 19% from the previous quarter
The company's gross profit has shrunk by 92% YoY but it rose by 17% QoQ
Bioline Rx's operating income has increased by 39% YoY but it has decreased by 6% from the previous quarter

Price vs fundamentals

How does BLRX's price correlate with its fundamentals

Growth

What is Bioline Rx's growth rate over time

Valuation

What is Bioline Rx stock price valuation
P/E
N/A
P/B
0.88
P/S
10.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.59
The stock's price to book (P/B) is 71% less than its 5-year quarterly average of 3.0 and 2.2% less than its last 4 quarters average of 0.9
The equity has contracted by 20% YoY and by 8% from the previous quarter
The revenue has plunged by 94% YoY but it has grown by 19% from the previous quarter
BLRX's P/S is 84% above its last 4 quarters average of 5.8

Efficiency

How efficient is Bioline Rx business performance
Bioline Rx's return on equity has shrunk by 100% YoY

Dividends

What is BLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BLRX.

Financial health

How did Bioline Rx financials performed over time
The company's total assets is 116% higher than its total liabilities
The company's current ratio fell by 30% YoY and by 19% QoQ
Bioline Rx's quick ratio has decreased by 30% YoY and by 20% QoQ
The debt is 46% smaller than the equity
The debt has declined by 34% year-on-year and by 11% since the previous quarter
The equity has contracted by 20% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.